Nearly 700 Drugs Sold In Beijing Are Markup-Free
This article was originally published in PharmAsia News
Beijing has increased the number of markup-free drugs sold at community health clinics by 180 to 699 this year and drugs covered by health insurance by 224 to 1,435.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.